[Pegylated interferons: pharmacological basis].
Macquin-Mavier
Isabelle
I
Service de Pharmacologie Clinique, CHU Henri Mondor, Assistance Publique, Hôpitaux de Paris, 94000 Créteil, France. isabelle.macquin-mavier@hmn.ap-hop-paris.fr
Hezode
Christophe
C
Dhumeaux
Daniel
D
D000042:Absorption; D000998:Antiviral Agents / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D002626:Chemistry, Pharmaceutical; D004338:Drug Combinations; D004347:Drug Interactions; D006207:Half-Life; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D008657:Metabolic Clearance Rate; D008970:Molecular Weight; D011092:Polyethylene Glycols / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D011994:Recombinant Proteins; D014018:Tissue Distribution
D000998:Antiviral Agents; D004338:Drug Combinations; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a